Literature DB >> 14737012

Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 gene.

Hirokazu Mizoguchi1, Hsiang-En Wu, Minoru Narita, Ichiro Sora, Scott F Hall, George R Uhl, Horace H Loh, Hiroshi Nagase, Leon F Tseng.   

Abstract

The G-protein activation induced by mu-opioid receptor agonists was determined in spinal cord membranes from two types of mu-opioid receptor knockout mice: mice with a disruption of exon 1 (MOR (Exon 1)-KO) or exons 2 and 3 (MOR (Exons 2 and 3)-KO) of the mu-opioid receptor gene. The G-protein activation induced by the opioid agonists was measured by monitoring the increases of guanosine-5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTP gamma S) binding. The mu-opioid receptor agonists (D-Ala(2),N-MePhe (4),Gly-ol(5)]enkephalin, endomorphin-1, endomorphin-2, morphine, morphine-6 beta-glucuronide, and fentanyl produced concentration-dependent increases of [(35)S]GTP gamma S binding to spinal cord membranes in wild-type mice, but not in MOR (Exon 1)-KO mice or MOR (Exons 2 and 3)-KO mice. On the other hand, the delta-opioid receptor agonist [D-Pen (2,5)]enkephalin, the kappa-opioid receptor agonist (-)U50,488H, or the ORL1-receptor agonist nociception increased [(35)S]GTP gamma S binding in the spinal cord membranes from both MOR (Exon 1)-KO mice and MOR (Exons 2 and 3)-KO mice to the same extent as in the corresponding wild-type mice. The results provide further information about the important roles of the sequences encoded within exon 1 and exons 2 and 3 of mu-opioid receptor gene for the activation of G-proteins by mu-opioid receptor agonists in the mouse spinal cord.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14737012     DOI: 10.1254/jphs.93.423

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

1.  mu-Opioid receptor-independent fashion of the suppression of sodium currents by mu-opioid analgesics in thalamic neurons.

Authors:  Keisuke Hashimoto; Taku Amano; Akiko Kasakura; George R Uhl; Ichiro Sora; Norio Sakai; Naoko Kuzumaki; Tsutomu Suzuki; Minoru Narita
Journal:  Neurosci Lett       Date:  2009-01-30       Impact factor: 3.046

Review 2.  The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?

Authors:  Ji Hoon Yoo; Ian Kitchen; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 3.  Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system.

Authors:  Patrick M Regan; Rajnish S Dave; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

Review 4.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

Review 5.  Regulation and Functional Implications of Opioid Receptor Splicing in Opioid Pharmacology and HIV Pathogenesis.

Authors:  Patrick M Regan; Dianne Langford; Kamel Khalili
Journal:  J Cell Physiol       Date:  2015-11-24       Impact factor: 6.384

6.  Morphine-induced MOR-1X and ASF/SF2 Expressions Are Independent of Transcriptional Regulation: Implications for MOR-1X Signaling.

Authors:  Patrick M Regan; Ilker K Sariyer; T Dianne Langford; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2015-12-28       Impact factor: 6.384

7.  Modulation of OPRM1 Alternative Splicing by Morphine and HIV-1 Nef.

Authors:  Martina Donadoni; Wenfei Huang; Shadan S Yarandi; Tricia H Burdo; Sulie L Chang; Ilker K Sariyer
Journal:  J Neuroimmune Pharmacol       Date:  2021-08-21       Impact factor: 4.147

8.  Larger Numbers of Glial and Neuronal Cells in the Periaqueductal Gray Matter of μ-Opioid Receptor Knockout Mice.

Authors:  Kazumasu Sasaki; Frank Scott Hall; George R Uhl; Ichiro Sora
Journal:  Front Psychiatry       Date:  2018-09-19       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.